Jiang Shan-Shan, Jiang Long, Weng De-Sheng, Li Yuan-Fang, Pan Qiu-Zhong, Zhao Jing-Jing, Tang Yan, Zhou Zhi-Wei, Xia Jian-Chuan
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.; Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, 310003, China.
Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.; Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
J Cancer. 2017 Feb 25;8(4):606-616. doi: 10.7150/jca.17356. eCollection 2017.
The purpose of this study was to examine and compare the prognostic value of different immunization-based scoring systems in patients with soft tissue sarcoma (STS). We conducted a retrospective study evaluating a cohort of 165 patients diagnosed with STS between July 2007 and July 2014. The relative Glasgow prognostic score (GPS) of these patients was calculated using 3 different systems: the traditional GPS system (tGPS), the modified GPS system 1 (m1GPS), and the modified GPS system 2 (m2GPS). Then, we evaluated the relationships between each GPS system and clinicopathological characteristics. The mean follow-up for survivors in the cohort was 73.7 months as of March 2015. The most favorable overall survival (OS) rate was associated with the score 0 groups, and the poorest progression-free survival (PFS) rate was associated with the score 2 groups, regardless of which system was used to calculate the score. Specifically, the m1GPS provided the greatest accuracy in predicting OS and PFS. Moreover, the same effect was observed in a separate analysis restricted to patients with metastases. Remarkably, in patients with a score of 2 as measured by all 3 systems, local treatment resulted in a poorer prognosis compared to patients with a score of 2 who did not receive local treatment. The GPS is a valuable prognostic marker and has the capability to predict the appropriate treatment strategy for STS patients with metastases. The modified GPS systems demonstrated superior prognostic and predictive value compared with the traditional GPS system.
本研究的目的是检验和比较不同基于免疫的评分系统在软组织肉瘤（STS）患者中的预后价值。我们进行了一项回顾性研究，评估了2007年7月至2014年7月期间确诊为STS的165例患者队列。使用3种不同系统计算这些患者的相对格拉斯哥预后评分（GPS）：传统GPS系统（tGPS）、改良GPS系统1（m1GPS）和改良GPS系统2（m2GPS）。然后，我们评估了每个GPS系统与临床病理特征之间的关系。截至2015年3月，该队列中幸存者的平均随访时间为73.7个月。无论使用哪种系统计算评分，总体生存率（OS）最有利的是评分0组，无进展生存率（PFS）最差的是评分2组。具体而言，m1GPS在预测OS和PFS方面提供了最高的准确性。此外，在仅针对有转移患者的单独分析中也观察到了相同的效果。值得注意的是，在所有3种系统测量评分为2的患者中，与未接受局部治疗的评分2患者相比，局部治疗导致预后较差。GPS是一种有价值的预后标志物，有能力为有转移的STS患者预测合适的治疗策略。与传统GPS系统相比，改良GPS系统显示出更好的预后和预测价值。
